<h2>Aurora Cannabis Expands Global Reach with EU-GMP Certification</h2>
<p>In a groundbreaking development, Aurora Cannabis Inc., a leader in the medical cannabis sector, has achieved the European Union Good Manufacturing Practice (EU-GMP) certification for its distribution center in Brampton, Ontario. This certification underscores Aurora's dedication to elevating its international export capabilities, strengthening its position as a major player in the global medical cannabis market. According to Jill Lau, Vice President of Canadian Operations at Aurora, this certification is a testament to their commitment to delivering top-tier medical cannabis products worldwide, ensuring consistent access for patients across the globe.</p>
<p>To attain this prestigious certification, Aurora's facilities had to comply with the EudraLex rules governing medicinal products in the EU, focusing on superior quality and consistency in manufacturing processes. This achievement not only enhances Aurora's export potential but also positions its distribution center as a key hub for receiving, distributing, and storing cannabis products internationally.</p>
<h2>New Opportunities for Cannabis Education in Germany</h2>
<p>In January 2025, Aurora Cannabis Inc. announced a significant educational initiative in partnership with the Erfurt University of Applied Sciences in Leuna, Germany. This collaboration aims to provide budding professionals with hands-on experience in medical cannabis cultivation through a six-month internship program. This program will offer students practical knowledge in various aspects of cannabis production, including cloning, cultivation, harvesting, packaging, and sanitation, while engaging in research and development projects at Aurora's EU-GMP-certified facility in Leuna.</p>
<p>Leuna's facility, a notable site approved for medical cannabis cultivation in Germany, provides a unique learning environment for students enrolled in the Horticultural Crop Production course. This partnership marks an important step in advancing cannabis education and expertise in Europe, nurturing the next generation of industry professionals.</p>
<h2>Enhancing Access to Medical Cannabis in Australia</h2>
<p>Further solidifying its commitment to patient care, Aurora Cannabis Inc., along with its subsidiary MedReleaf Australia, has removed the requirement for concession cards to access its IndiMed brand products. This policy shift in February 2025 enables broader access for Australian patients to obtain essential medical cannabis treatments without the additional barrier of a concession card.</p>
<p>This strategic decision highlights Aurora's focus on improving accessibility and affordability of medical cannabis therapies for patients in Australia. By eliminating the concession card necessity, Aurora is fostering a more inclusive approach, ensuring that patients in need can benefit from their high-quality cannabis products.</p>
<p>#CannabisNews #MedicalCannabis #CBDTrends #EUCompliance #CannabisEducation</p>